Scientometrics
Copyright ©The Author(s) 2023.
World J Gastroenterol. Oct 28, 2023; 29(40): 5593-5617
Published online Oct 28, 2023. doi: 10.3748/wjg.v29.i40.5593
Table 2 Clinical trials in phase 3 and phase 4 (or phase 2/3)
No.
Trial ID
Status
Phases
Start date
Title
1NCT00503321TerminatedPhase 2/3October 1, 2006Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
2EUCTR2017-004896-30-IENot recruitingPhase 3July 6, 2018A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in Combination with Chemotherapy as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic LAG-3 Positive Gastric or Gastroesophageal Junction Adenocarcinoma
3NCT04078152Active, not recruitingPhase 4September 5, 2019Durvalumab Long-Term Safety and Efficacy Study
4ChiCTR2000039110RecruitingPhase 4October 14, 2020Effect of immunotherapy combined with chemotherapy on gastric cancer
5NCT05002686RecruitingPhase 2/3August 7, 2021Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
6NCT05152147RecruitingPhase 3December 2, 2021A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
7NCT05270824Not yet recruitingPhase 3March 1, 2022Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
8NCT05325528RecruitingPhase 2/3April 4, 2022Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
9NCT05677490Not yet recruitingPhase 3January 6, 2023mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
10NCT05699655Not yet recruitingPhase 2/3March 1, 2023Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV, Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer